Subcutaneous once-weekly semaglutide 2.4 mg, a GLP1 receptor agonist, was associated with a statistically significant 20% reduction in major adverse cardiovascular events (MACE) compared with placebo, ...
Dr. Alexandra T. Lucas (Pediatrics): A 19-year-old man was admitted to the pediatric intensive care unit (PICU) of this hospital because of shock, multiple organ failure, and rash. The patient had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results